Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS Genet ; 4(1): e6, 2008 Jan.
Article in English | MEDLINE | ID: mdl-18193945

ABSTRACT

Mutations in optic atrophy 1 (OPA1), a nuclear gene encoding a mitochondrial protein, is the most common cause for autosomal dominant optic atrophy (DOA). The condition is characterized by gradual loss of vision, color vision defects, and temporal optic pallor. To understand the molecular mechanism by which OPA1 mutations cause optic atrophy and to facilitate the development of an effective therapeutic agent for optic atrophies, we analyzed phenotypes in the developing and adult Drosophila eyes produced by mutant dOpa1 (CG8479), a Drosophila ortholog of human OPA1. Heterozygous mutation of dOpa1 by a P-element or transposon insertions causes no discernable eye phenotype, whereas the homozygous mutation results in embryonic lethality. Using powerful Drosophila genetic techniques, we created eye-specific somatic clones. The somatic homozygous mutation of dOpa1 in the eyes caused rough (mispatterning) and glossy (decreased lens and pigment deposition) eye phenotypes in adult flies; this phenotype was reversible by precise excision of the inserted P-element. Furthermore, we show the rough eye phenotype is caused by the loss of hexagonal lattice cells in developing eyes, suggesting an increase in lattice cell apoptosis. In adult flies, the dOpa1 mutation caused an increase in reactive oxygen species (ROS) production as well as mitochondrial fragmentation associated with loss and damage of the cone and pigment cells. We show that superoxide dismutase 1 (SOD1), Vitamin E, and genetically overexpressed human SOD1 (hSOD1) is able to reverse the glossy eye phenotype of dOPA1 mutant large clones, further suggesting that ROS play an important role in cone and pigment cell death. Our results show dOpa1 mutations cause cell loss by two distinct pathogenic pathways. This study provides novel insights into the pathogenesis of optic atrophy and demonstrates the promise of antioxidants as therapeutic agents for this condition.


Subject(s)
Antioxidants/therapeutic use , Drosophila Proteins/genetics , GTP Phosphohydrolases/genetics , Membrane Proteins/genetics , Optic Atrophy, Autosomal Dominant/etiology , Optic Atrophy, Autosomal Dominant/genetics , Optic Atrophy, Autosomal Dominant/therapy , Amino Acid Sequence , Animals , DNA Transposable Elements/genetics , Disease Models, Animal , Drosophila , Drosophila Proteins/chemistry , Drosophila Proteins/metabolism , Eye/ultrastructure , GTP Phosphohydrolases/chemistry , GTP Phosphohydrolases/metabolism , Gene Dosage , Genes, Dominant , Genes, Insect , Genetic Techniques , Homozygote , Humans , Membrane Proteins/chemistry , Membrane Proteins/metabolism , Molecular Sequence Data , Mutagenesis, Insertional , Mutation , Optic Atrophy, Autosomal Dominant/pathology , Penetrance , Protein Structure, Tertiary , Sequence Homology, Amino Acid , Superoxide Dismutase/therapeutic use , Vitamin E/therapeutic use
2.
Biol Bull ; 212(2): 169-75, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17438209

ABSTRACT

Mitochondria, as portable generators that power synaptic function, regulate the ATP supply and calcium homeostasis in the neuron. As molecular interactions within the synapses before and after the potentiation are beginning to be elucidated, the deciding moment during the tetanic stimulation that gives rise to the strengthening of the synapse remains a mystery. Here, I recorded electrically from an intact Drosophila nervous system, while simultaneously using time-lapse confocal microscopy to visualize mitochondria labeled with green fluorescent protein. I show that tetanic stimulation triggers a fast delivery of mitochondria to the synapse, which facilitates synaptic potentiation. Rotenone, an inhibitor of mitochondrial electron transport chain complex I, suppresses mitochondrial transport and abolishes the potentiation of the synapse. Expression of neurofibromin, which improves mitochondrial ATP synthesis in the neuron, enhances the movements of mitochondria to the synapse and promotes post-tetanic potentiation. These findings provide unprecedented evidence that the mitochondrial delivery to the synapse is critical for cellular learning.


Subject(s)
Drosophila/physiology , Mitochondria/physiology , Motor Neurons/physiology , Neuromuscular Junction/physiology , Synaptic Transmission/physiology , Adenosine Triphosphate/metabolism , Animals , Axons/physiology , Axons/ultrastructure , Electrophysiology , Green Fluorescent Proteins , Mitochondria/drug effects , Mitochondria/ultrastructure , Neurofibromin 1/pharmacology , Rotenone/toxicity
3.
Nat Genet ; 39(4): 476-85, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17369827

ABSTRACT

We investigated the pathophysiology of neurofibromatosis-1 (NF1) in Drosophila melanogaster by inactivation or overexpression of the NF1 gene. NF1 gene mutants had shortened life spans and increased vulnerability to heat and oxidative stress in association with reduced mitochondrial respiration and elevated reactive oxygen species (ROS) production. Flies overexpressing NF1 had increased life spans, improved reproductive fitness, increased resistance to oxidative and heat stress in association with increased mitochondrial respiration and a 60% reduction in ROS production. These phenotypic effects proved to be modulated by the adenylyl cyclase/cyclic AMP (cAMP)/protein kinase A pathway, not the Ras/Raf pathway. Treatment of wild-type D. melanogaster with cAMP analogs increased their life span, and treatment of NF1 mutants with metalloporphyrin catalytic antioxidant compounds restored their life span. Thus, neurofibromin regulates longevity and stress resistance through cAMP regulation of mitochondrial respiration and ROS production, and NF1 may be treatable using catalytic antioxidants.


Subject(s)
Antioxidants/therapeutic use , Drosophila melanogaster/genetics , Longevity/genetics , Mitochondria/physiology , Neurofibromatosis 1/drug therapy , Neurofibromin 1/genetics , Animals , Animals, Genetically Modified , Cyclic AMP/analogs & derivatives , Disease Models, Animal , Female , Gene Expression Regulation , Male , Metalloporphyrins/therapeutic use , Mitochondria/metabolism , Models, Biological , Neurofibromatosis 1/pathology , Phenotype , Reactive Oxygen Species/metabolism
4.
Hum Mol Genet ; 15(7): 1087-98, 2006 Apr 01.
Article in English | MEDLINE | ID: mdl-16513807

ABSTRACT

Neurofibromatosis type I (NFI) is a common genetic disorder that causes nervous system tumors, and learning and memory defects in humans, and animal models. We identify a novel growth factor stimulated adenylyl cyclase (AC) pathway in the Drosophila brain, which is disrupted by mutations in the epidermal growth factor receptor (EGFR), neurofibromin (NF1) and Ras, but not Galpha(s). This is the first demonstration in a metazoan that a receptor tyrosine kinase (RTK) pathway, acting independently of the heterotrimeric G-protein subunit Galpha(s), can activate AC. We also show that Galpha(s) is the major Galpha isoform in fly brains, and define a second AC pathway stimulated by serotonin and histamine requiring NF1 and Galpha(s), as well as a third, classical Galpha(s)-dependent AC pathway, which is stimulated by Phe-Met-Arg-Phe-amide (FMRFamide) and dopamine. Using mutations and deletions of the human NF1 protein (hNF1) expressed in Nf1 mutant flies, we show that Ras activation by hNF1 is essential for growth factor stimulation of AC activity. Further, we demonstrate that sequences in the C-terminal region of hNF1 are sufficient for NF1/Galpha(s)-dependent neurotransmitter stimulated AC activity, and for rescue of body size defects in Nf1 mutant flies.


Subject(s)
Adenylyl Cyclases/metabolism , Gene Expression Regulation , Mutation , Neurofibromin 1/genetics , Signal Transduction , ras Proteins/metabolism , Animals , Animals, Genetically Modified , Body Size/genetics , Drosophila , Enzyme Activation , GTP-Binding Proteins/metabolism , GTPase-Activating Proteins/metabolism , Gene Deletion , Growth Substances/metabolism , Growth Substances/pharmacology , Humans , Models, Biological , Neurofibromin 1/metabolism , Neurofibromin 1/pharmacology , Neurotransmitter Agents , Protein Structure, Tertiary , Signal Transduction/genetics , ras Proteins/pharmacology
5.
Biol Bull ; 207(2): 162, 2004 Oct.
Article in English | MEDLINE | ID: mdl-27690591
6.
Cancer Cell ; 3(3): 297-302, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12676587

ABSTRACT

Representational difference analysis (RDA) of human breast cancer was used to discover a novel amplicon located at chromosomal region 8q24.3. We examined a series of breast cancer samples harboring amplification of this region and determined that KCNK9 is the sole overexpressed gene within the amplification epicenter. KCNK9 encodes a potassium channel that is amplified from 3-fold to 10-fold in 10% of breast tumors and overexpressed from 5-fold to over 100-fold in 44% of breast tumors. Overexpression of KCNK9 in cell lines promotes tumor formation and confers resistance to both hypoxia and serum deprivation, suggesting that its amplification and overexpression plays a physiologically important role in human breast cancer.


Subject(s)
Gene Amplification , Potassium Channels/genetics , Potassium Channels/metabolism , Animals , Breast Neoplasms/genetics , Cell Line , Cell Transplantation , Chromosomes, Human, Pair 8 , DNA Probes , Female , Gene Expression Regulation, Neoplastic , Genome, Human , Humans , Mice , Molecular Sequence Data , Oncogenes , Physical Chromosome Mapping , Sequence Tagged Sites , Transplantation, Heterologous
SELECTION OF CITATIONS
SEARCH DETAIL
...